drugset / Trial / NCT04258956
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy
NaSingle-groupOpen-labelTreatment
Summary
To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at least of imatinib and sunitinib) in terms of progression-free survival (PFS)
Timeline
- Start
- 2019-04-30
- Primary completion
- 2021-04-30
- Completion
- 2023-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Axitinib | Small molecule | 5 mg | Oral |